Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;11(4):897-902.
doi: 10.14283/jpad.2024.83.

Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?

R Korologou-Linden  1 , J Kalsi, D Kafetsouli, A Olawale, A Iwata, D Wingfield, D Mummery, B Hayhoe, O Robinson, A Majeed, L T Middleton
Affiliations
Review

Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?

R Korologou-Linden et al. J Prev Alzheimers Dis. 2024.

Abstract

Recent positive trials for novel disease modifying therapies of anti-amyloid monoclonal antibodies represent a paradigm shift in the prevention and management of Alzheimer's disease, a relentlessly progressive and debilitating disease of old age. The reported efficacy of these new agents when given early in the disease trajectory is dependent on an early and accurate disease diagnosis, which is currently based on cerebrospinal fluid tests or/and neuro-imaging studies such as positron emission tomography. These confirmatory tests provide in vivo evidence of the pathological signature of Alzheimer's disease, of increased cerebral amyloid and tau burden and neurodegeneration. The emergence of blood-based biomarkers represents another breakthrough, offering a less invasive and scalable diagnostic tool that could be applied in both primary and specialist care settings, potentially revolutionizing Alzheimer's disease clinical pathways. However, healthcare systems face challenges in the adoption of these new technologies and therapies due to diagnostic and treatment capacity constraints, as well as financial and infrastructure requirements.

Keywords: Alzheimer’s disease; Donanemab; Lecanemab; blood-based biomarkers; monoclonal antibody therapies.

PubMed Disclaimer

Conflict of interest statement

Dr. Middleton reports grants from Johnson and Johnson, Merck, Takeda, Gates Ventures, Eisai, NIHR, UKRI, and research funding from the Davos Alzheimer’s Collaborative (DAC), outside the submitted work; all to Imperial College London. Dr. Wingfield reports research funding from NIHR and DAC, outside the submitted work. All other authors have no conflicts of interest to disclose.

References

    1. World Health Organization Fact sheets of dementia. 2023 Mar. https://www.who.int/news-room/fact-sheets/detail/dementia
    1. 2020 Alzheimer's disease facts and figures. Alzheimer's and Dementia. 2020 Mar 1;16(3):391–460. doi: 10.1002/alz.12068. - DOI - PubMed
    1. Wu YT, Beiser AS, Breteler MMB, Fratiglioni L, Helmer C, Hendrie HC, et al. The changing prevalence and incidence of dementia over time - current evidence. Nat Rev Neurol. 2017;13(6):327–339. 10.1038/nrneurol.2017.63 PubMed PMID: 28497805; Jun 1. - DOI - PubMed
    1. Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016 Jul 30;8(1) doi: 10.1186/s13195-016-0188-8. - DOI - PMC - PubMed
    1. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol. 1994;51(9):888–895. 10.1001/archneur.1994.00540210060013 PubMed PMID: 8080388. - DOI - PubMed

MeSH terms